Cancel
Known information
- Holds a B.A. with honors from the Johns Hopkins University
- Earned a M.D. from Tufts University School of Medicine
- Completed a Residency in Internal Medicine at the University Health Center of Pittsburgh
- Completed a Fellowship in Allergy and Clinical Immunology at the Johns Hopkins University School of Medicine
- Previously served as CMO of Acceleron Pharma
- Was instrumental in the preparation of the biologics license application for luspatercept
- Served as CMO of Immunovant
- Directed the Phase 3 development program and regulatory filings of caplacizumab at Ablynx NV
- Served as Senior Vice President and Head of Global Clinical Development at Stallergenes SA
- Was Vice President and U.S. Medical Franchise Head – Respiratory and Dermatology at Novartis Pharmaceuticals
- Spent seven years at Merck in increasingly strategic roles in worldwide regulatory affairs and clinical development
- Served as a Medical Officer at the U.S. Food & Drug Administration’s Center for Biologics Evaluation and Research
- Spent several years in clinical practice
About MeiraGTx
MeiraGTx is a biotechnology firm specializing in the development of gene therapies for serious diseases, with a focus on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia.
Report inaccurate information
